Cited by 117Dementia and Cognitive Impairment ResearchMedical Image Segmentation TechniquesAlzheimer's disease research and treatments

Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls

Open access
Chou, Yi-Yu, Leporé, Natasha, Avedissian, Christina, Madsen, Sarah K., Parikshak, Neelroop, Hua, Xue, Shaw, Leslie M., Trojanowski, John Q. +3 more·2009·NeuroImage

Abstract

We aimed to improve on the single-atlas ventricular segmentation method of (Carmichael, O.T., Thompson, P.M., Dutton, R.A., Lu, A., Lee, S.E., Lee, J.Y., Kuller, L.H., Lopez, O.L., Aizenstein, H.J., Meltzer, C.C., Liu, Y., Toga, A.W., Becker, J.T., 2006. Mapping ventricular changes related to dementia and mild cognitive impairment in a large community-based cohort. IEEE ISBI. 315-318) by using multi-atlas segmentation, which has been shown to lead to more accurate segmentations (Chou, Y., Leporé, N., de Zubicaray, G., Carmichael, O., Becker, J., Toga, A., Thompson, P., 2008. Automated ventricular mapping with multi-atlas fluid image alignment reveals genetic effects in Alzheimer's disease, NeuroImage 40(2): 615-630); with this method, we calculated minimal numbers of subjects needed to detect correlations between clinical scores and ventricular maps. We also assessed correlations between emerging CSF biomarkers of Alzheimer's disease pathology and localizable deficits in the brain, in 80 AD, 80 mild cognitive impairment (MCI), and 80 healthy controls from the Alzheimer's Disease Neuroimaging Initiative. Six expertly segmented images and their embedded parametric mesh surfaces were fluidly registered to each brain; segmentations were averaged within subjects to reduce errors. Surface-based statistical maps revealed powerful correlations between surface morphology and 4 variables: (1) diagnosis, (2) depression severity, (3) cognitive function at baseline, and (4) future cognitive decline over the following year. Cognitive function was assessed using the mini-mental state exam (MMSE), global and sum-of-boxes clinical dementia rating (CDR) scores, at baseline and 1-year follow-up. Lower CSF Abeta(1-42) protein levels, a biomarker of AD pathology assessed in 138 of the 240 subjects, were correlated with lateral ventricular expansion. Using false discovery rate (FDR) methods, 40 and 120 subjects, respectively, were needed to discriminate AD and MCI from normal groups. 120 subjects were required to detect correlations between ventricular enlargement and MMSE, global CDR, sum-of-boxes CDR and clinical depression scores. Ventricular expansion maps correlate with pathological and cognitive measures in AD, and may be useful in future imaging-based clinical trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuroimage.2009.02.015

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Short-term randomized controlled trials, longer-term open-label extensions, and long-term observational prospective clinical cohort effectiveness studies support the safety and benefits of anti-AD treatments in combination, most frequently as memantine added on to a stable regimen of background cholinesterase inhibitor treatment.

    “Short-term (6-12 months) RCTs (level I evidence), longer-term (12-36 months) openlabel extensions of RCTs (level II or III evidence), and long-term (2 to 5-plus years) observational prospective clinical cohort effectiveness studies (level II evidence) support the safety and benefits of anti-AD treatments in combination, most frequently as memantine added on to a stable regimen of background ChEI”

    From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [116]

  • Longer-term prospective observational clinical patient cohort studies report reduced clinical decline in patients with AD treated at any stage.

    “Longer-term prospective observational clinical patient cohort studies report reduced clinical decline in patients with AD treated at any stage.[114][115][116][117][118][119]”

    From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [116]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Gramkow C 1996 Registration of 2D and 3D medical images Master’s thesis, Danish Technical University Copenhagen, Denmark
  2. Thompson PM Hayashi KM de Zubicaray G Janke AL Rose SE Semple J 2004a Dynamics of gray matter loss in Alzheimer’s disease J Neurosci 23 994 1005 12574429 PMC6741905

Cited by

Sorted by citations

Authors
Chou, Y.-Y., Leporé, N., Avedissian, C., Madsen, S. K., Parikshak, N., Hua, X., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Toga, A. W., & Thompson, P. M.
Affiliations
  • University of California, Los Angeles (US)
  • University of Pennsylvania (US)
  • University of California, San Francisco (US)
Corresponding author
Thompson, Paul M.
Venue
NeuroImage
Publisher
Elsevier BV
Published
2009-06
Volume
46
Issue
2
Pages
394-410
ISSN
1053-8119 (ISSN-L)
OpenAlex
W2017516371
Cited by
117
References
93
Citations by year
2026: 5 · 2025: 4 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 5 · 2014: 9 · 2013: 12 · 2012: 3
FWCI
8.45
Type
journal article
Language
en
Open access
Locations
  • NeuroImage (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Center for Research Resources (AG016570, EB01651, LM05639, RR019771)
  • National Institutes of Health (U01 AG024904)
  • Pfizer
  • Foundation for the National Institutes of Health
  • GlaxoSmithKline
  • National Institute on Aging
  • Alzheimer's Disease Neuroimaging Initiative
  • U.S. National Library of Medicine
  • National Institute of Biomedical Imaging and Bioengineering
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Physical Sciences › Computer Science › Computer Vision and Pattern Recognition › Medical Image Segmentation Techniques
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, mild cognitive impairment, ventriculomegaly, lateral ventricle, cerebrospinal fluid biomarkers, amyloid-beta, tau protein, multi-atlas segmentation, cognitive decline, depression, sample size determination, Alzheimer's Disease Neuroimaging Initiative, brain atrophy, Clinical Dementia Rating, Mini-Mental State Examination, false discovery rate
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, California, Cerebral Ventricles, Cognition Disorders, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Reference Values, Sensitivity and Specificity, Statistics as Topic, Reproducibility of Results, Biomarkers, Comorbidity, Incidence, Amyloid beta-Peptides, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review